1243 related articles for article (PubMed ID: 23848260)
1. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development.
Bigal ME; Walter S; Rapoport AM
Headache; 2013 Sep; 53(8):1230-44. PubMed ID: 23848260
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic antibodies against CGRP or its receptor.
Bigal ME; Walter S; Rapoport AM
Br J Clin Pharmacol; 2015 Jun; 79(6):886-95. PubMed ID: 25614243
[TBL] [Abstract][Full Text] [Related]
3. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine.
Maasumi K; Michael RL; Rapoport AM
Drugs; 2018 Jun; 78(9):913-928. PubMed ID: 29869205
[TBL] [Abstract][Full Text] [Related]
4. Patent watch: Migraine therapies targeting the CGRP pathway: intellectual property landscape.
Fiala JL; Lowery D
Nat Rev Drug Discov; 2016 Jan; 15(1):8-9. PubMed ID: 26669672
[No Abstract] [Full Text] [Related]
5. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
[TBL] [Abstract][Full Text] [Related]
6. Targeting calcitonin gene-related peptide: a new era in migraine therapy.
Charles A; Pozo-Rosich P
Lancet; 2019 Nov; 394(10210):1765-1774. PubMed ID: 31668411
[TBL] [Abstract][Full Text] [Related]
7. Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date.
Pellesi L; Guerzoni S; Pini LA
Clin Pharmacol Drug Dev; 2017 Nov; 6(6):534-547. PubMed ID: 28409893
[TBL] [Abstract][Full Text] [Related]
8. Erenumab in the treatment of migraine.
Jain S; Yuan H; Spare N; Silberstein SD
Pain Manag; 2018 Nov; 8(6):415-426. PubMed ID: 30235976
[TBL] [Abstract][Full Text] [Related]
9. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
Hargreaves R; Olesen J
Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
[TBL] [Abstract][Full Text] [Related]
10. Calcitonin gene-related peptide (CGRP) antagonists and migraine: is this a new era?
Goadsby PJ
Neurology; 2008 Apr; 70(16):1300-1. PubMed ID: 18413584
[No Abstract] [Full Text] [Related]
11. Antigens and Antibodies in Disease With Specifics About CGRP Immunology.
Taylor FR
Headache; 2018 Nov; 58 Suppl 3():230-237. PubMed ID: 30187471
[TBL] [Abstract][Full Text] [Related]
12. CGRP as the target of new migraine therapies - successful translation from bench to clinic.
Edvinsson L; Haanes KA; Warfvinge K; Krause DN
Nat Rev Neurol; 2018 Jun; 14(6):338-350. PubMed ID: 29691490
[TBL] [Abstract][Full Text] [Related]
13. The vasodilatory activity of CGRP: a response.
Bigal ME; Walter S; Rapoport AM
Headache; 2014 Apr; 54(4):748-9. PubMed ID: 24697226
[No Abstract] [Full Text] [Related]
14. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine.
Salvatore CA; Hershey JC; Corcoran HA; Fay JF; Johnston VK; Moore EL; Mosser SD; Burgey CS; Paone DV; Shaw AW; Graham SL; Vacca JP; Williams TM; Koblan KS; Kane SA
J Pharmacol Exp Ther; 2008 Feb; 324(2):416-21. PubMed ID: 18039958
[TBL] [Abstract][Full Text] [Related]
15. Calcitonin gene-related peptide (CGRP): a new target for migraine.
Russo AF
Annu Rev Pharmacol Toxicol; 2015; 55():533-52. PubMed ID: 25340934
[TBL] [Abstract][Full Text] [Related]
16. Targeting CGRP: A New Era for Migraine Treatment.
Wrobel Goldberg S; Silberstein SD
CNS Drugs; 2015 Jun; 29(6):443-52. PubMed ID: 26138383
[TBL] [Abstract][Full Text] [Related]
17. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment.
Edvinsson L
Br J Clin Pharmacol; 2015 Aug; 80(2):193-9. PubMed ID: 25731075
[TBL] [Abstract][Full Text] [Related]
18. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():276-290. PubMed ID: 30403405
[TBL] [Abstract][Full Text] [Related]
19. CGRP Monoclonal Antibodies for Migraine: Rationale and Progress.
Yuan H; Lauritsen CG; Kaiser EA; Silberstein SD
BioDrugs; 2017 Dec; 31(6):487-501. PubMed ID: 29116598
[TBL] [Abstract][Full Text] [Related]
20. Calcitonin gene-related peptide (receptor) antibodies: an exciting avenue for migraine treatment.
MaassenVanDenBrink A; Terwindt GM; van den Maagdenberg AMJM
Genome Med; 2018 Feb; 10(1):10. PubMed ID: 29471874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
